Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 6 of 6 for “"talazoparib"”.
-
Tracking Treatment Response and Resistance to Parp Inhibition (Talazoparib) In Hereditary Pancreatic Cancer.
… compared to placebo (7.4 months vs 3.8 months). Talazoparib, a second generation PARP inhibitor, is 20-200-fold more efficacious compared to older PARP inhibitors. In 2018, Talazoparib was FDA approved to treat <em>BRCA</em>-mutant, HER2-negative breast cancer and is still in early phase trials …
-
Role of C-Met and Egfr In Acquired Resistance to Parp Inhibitors In Triple-Negative Breast Cancer
… polymerase (PARP) inhibitors, olaparib and talazoparib, were recently approved for metastatic breast cancer (including triple-negative breast cancer) in patients with a germline <em>BRCA1/2</em> mutation. Despite impressive response rates of ~60%, the prolongation in median progression-free …
-
Δεδομένα φαρμακοεπαγρύπνησης των PARP inhibitors στον καρκίνο ωοθηκών και μαστού / Pharmacovigilance data of PARP inhibitors in ovarian and breast cancer
… αναστολείς Οlaparib, Niraparib, Rucaparib και Talazoparib που ήδη έχουν πάρει έγκριση από τις ρυθμιστικές αρχές άλλα και για αυτούς που βρίσκονται σε πειραματικό στάδιο όπως οι Veliparib, Saruparib, Pamiparib και Fluzoparib. Για κάθε φάρμακο μελετήθηκαν οι κλινικές μελέτες φάσης Ι,ΙΙ ή ΙΙΙ που …
-
ROR1 and Rab27b – novel biomarkers for chemoresistance in ovarian cancer
… of four drugs; cisplatin, carboplatin, taxol and talazoparib for the cell lines were determined. qPCR was carried out to investigate gene expression levels of ROR1, Rab27b and EMT markers in response to drug treatments for each cell line. ELISA’s and Immunocytochemistry were carried out to …
-
The impact of chronic loss of STAG2 on DNA damage repair and the epigenome in acute myeloid leukaemia
… as a biomarker for response to Olaparib and Talazoparib in AML. Additionally, NGS studies revealed modest transcriptomic changes accompanied by altered global DNA methylation in cells depleted of STAG2. Excitingly, enrichment analysis of DEGs and DMRs revealed many novel and some unexpected …
-
Receptor Tyrosine Kinases-Mediated Acquired Parp Inhibitor Resistance In Breast Cancer
<p>Leveraging compromised DNA damage repair (DDR) pathways commonly found in tumor cells, a classic strategy in cancer therapy is inducing excessive DNA damage to cause cancer cell death. Small molecule poly(ADP-ribose) polymerase (PARP) inhibitors (PARP-is) have been approved for clinical use in …